home / stock / esalf / esalf short
Short Information | Eisai Co Ltd (OTCMKTS:ESALF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 3,438 |
Total Actual Volume | 41,995 |
Short Trends | |
---|---|
Cover Days | 7 |
Short Days | 12 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 172 |
Average Short Percentage | 56.75% |
Is there a ESALF Short Squeeze or Breakout about to happen?
See the ESALF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-20-2024 | $0 | $42.84 | $0 | $0 | 70 | 20 | 28.57% |
05-16-2024 | $0 | $42.84 | $0 | $0 | 52 | 41 | 78.85% |
05-14-2024 | $43.655 | $42.84 | $43.655 | $42.54 | 362 | 61 | 16.85% |
05-13-2024 | $44.67 | $44.67 | $44.67 | $44.67 | 167 | 158 | 94.61% |
05-09-2024 | $0 | $42.55 | $0 | $0 | 2 | 2 | 100% |
05-06-2024 | $42.585 | $42.55 | $42.585 | $42.55 | 925 | 73 | 7.89% |
05-03-2024 | $42.945 | $43.67 | $43.67 | $42.945 | 1,330 | 530 | 39.85% |
05-01-2024 | $42.12 | $42.12 | $42.12 | $42.12 | 190 | 190 | 100% |
04-29-2024 | $40.82 | $40.82 | $40.82 | $40.82 | 177 | 112 | 63.28% |
04-26-2024 | $0 | $40.005 | $0 | $0 | 4 | 4 | 100% |
04-24-2024 | $40.31 | $40.1 | $41.12 | $40.1 | 31,467 | 424 | 1.35% |
04-19-2024 | $38.79 | $38.95 | $38.95 | $38.79 | 925 | 500 | 54.05% |
04-18-2024 | $38.1 | $37.53 | $38.1 | $37.53 | 2,125 | 383 | 18.02% |
04-17-2024 | $38.18 | $38.11 | $38.18 | $38.11 | 899 | 31 | 3.45% |
04-15-2024 | $0 | $39 | $0 | $0 | 37 | 37 | 100% |
04-12-2024 | $0 | $39 | $0 | $0 | 90 | 49 | 54.44% |
04-11-2024 | $39 | $39 | $39 | $39 | 120 | 120 | 100% |
04-10-2024 | $39.19 | $39.2 | $39.2 | $38.59 | 2,260 | 160 | 7.08% |
04-09-2024 | $0 | $40.375 | $0 | $0 | 43 | 43 | 100% |
04-04-2024 | $40.31 | $40.3 | $40.31 | $39.15 | 750 | 500 | 66.67% |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and...
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures TOKYO, May 13, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house disc...
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...